MINNEAPOLIS - Clinical-stage biotechnology company Celcuity Inc. announced on Monday, November 9, that the United States Food and Drug Administration has formally accepted its supplemental New Drug Application (sNDA) for Revtorpyk (gedatolisib). The regulatory filing seeks approval for the targeted multi-kinase inhibitor in adult patients presenting with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer harboring PIK3CA genetic mutations whose disease progressed following prior endocrine therapy.
The regulatory submission is supported by robust clinical data generated in the pivotal Phase 3 VIKTORIA-1 clinical trial, which enrolled 392 evaluable patients across international cancer research centers. The study evaluated gedatolisib administered in combination with fulvestrant and palbociclib (triplet regimen) compared against standard-of-care alpelisib and fulvestrant. Blinded independent central review established that the gedatolisib triplet achieved a median progression-free survival of 9.3 months, compared to 2.0 months in the control arm, representing a 76 percent reduction in the risk of disease progression or death.
The Chief Executive Officer of Celcuity stated in the corporate announcement: "FDA acceptance of our supplemental application represents an important milestone toward delivering a differentiated therapeutic option to oncology patients. The robust Phase 3 survival data demonstrate that targeting both PI3K and mTOR pathways provides meaningful clinical benefit for individuals confronting refractory disease." Clinical oncology researchers commended the regulatory progression.
The safety analysis demonstrated favorable tolerability across active treatment cohorts. Discontinuations attributable to treatment-related adverse events occurred in only 2.6 percent of patients receiving the gedatolisib triplet, compared to 7.1 percent among those treated with standard-of-care regimens. Clinically significant grade 3 hyperglycemia was documented in only 15.0 percent of gedatolisib patients, substantially lower than historical rates observed with first-generation alpha-specific PI3K inhibitors.
FDA sets 2027 review target as PIK3CA mutations drive resistance
PIK3CA activating mutations occur in approximately 40 percent of hormone receptor-positive metastatic breast cancer cases, frequently conferring resistance to front-line CDK4/6 inhibitor combinations. By simultaneously suppressing all four class I PI3K isoforms and mTOR complexes, gedatolisib prevents compensatory feedback signaling that routinely circumvents single-node inhibitors, establishing durable pathway suppression without excessive systemic toxicity.
The Food and Drug Administration assigned a standard Prescription Drug User Fee Act review target for the first half of 2027. Commercial readiness teams at Celcuity have initiated distribution planning across specialized cancer care networks and third-party payer formularies to support timely patient access upon potential commercial authorization.
Clinical oncology researchers highlighted that simultaneous multi-node kinase inhibition represents a transformative advancement in overcoming acquired therapeutic resistance in advanced breast cancer. By providing sustained pathway suppression without excessive systemic toxicity, the gedatolisib triplet regimen offers an effective and tolerable clinical alternative for heavily pre-treated oncology patients. Regulatory acceptance of the supplemental New Drug Application advances Celcuity toward potential commercialization, supported by robust randomized Phase 3 clinical trial evidence. Medical oncologists emphasized that integrating comprehensive genomic profiling into routine clinical practice ensures that patients harboring PIK3CA activating mutations receive timely access to precision combination therapies. Expanding the armamentarium of targeted oral and injectable anti-cancer agents significantly improves long-term survival expectations for individuals confronting difficult-to-treat metastatic malignancies.
Biopharmaceutical industry analysts pointed out that targeted multi-kinase inhibitor combinations establish higher clinical response benchmarks for refractory oncology patients. Medical research directors emphasized that minimizing toxic metabolic side effects significantly enhances long-term patient compliance during intensive therapy. Global healthcare advocates stated that timely regulatory reviews accelerate patient access to life-prolonging precision medications across oncology centers worldwide. Translational oncology specialists pointed out that precision multi-pathway targeting represents a crucial breakthrough for patients with refractory genetic mutations. Advancing innovative combination therapies through rigorous regulatory evaluations provides durable therapeutic hope for individuals confronting advanced malignancies.
